PTC Therapeutics | PTCT - Assets


PTC Therapeutics reported $2.87B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
TG Therapeutics USD 1.53B 465.58M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026
Xencor USD 736.85M 138.65M Mar/2026